PepVault
/ database / Gut Barrier Modulator

Larazotide

Also: AT-1001

Clinical-grade tight-junction modulator — most advanced for celiac.

Evidence
emerging
Legal status
research only
Half-life
<1 hour
Routes
oral
View on Limitless LifeAdd to compare
What it is

Larazotide acetate is the most-studied tight-junction modulator in clinical development, with multiple Phase 2 trials in celiac disease showing reduced symptoms on gluten challenge.

Mechanism

Tight junction regulator — reduces intestinal permeability.

Outcomes it's matched to
Safety

Well tolerated in trials.

Legal context

Not approved. Investigational.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault